Cited by 1,110Liver Disease Diagnosis and TreatmentInflammasome and immune disordersLiver physiology and pathology

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

Open access

Mridha, Auvro R., Wree, Alexander, Robertson, Avril A.B., Yeh, Matthew M., Johnson, Casey D., Van Rooyen, Derrick M., Haczeyni, Fahrettin, Teoh, Narci C.-H., Savard, Christopher, Ioannou, George N., Masters, Seth L., Schroder, Kate, Cooper, Matthew A., Feldstein, Ariel E., Farrell, Geoffrey C.·2017·Journal of Hepatology

DOI 10.1016/j.jhep.2017.01.022PMC PMC6536116

Open this paper in CoChat — free account

Abstract

Background & aims NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alcoholic fatty liver disease (NAFLD). We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis.Methods We fed foz/foz and wild-type mice an atherogenic diet for 16weeks, gavaged MCC950 or vehicle until 24weeks, then determined NAFLD phenotype. In mice fed an methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle for 6weeks and determined the effects on liver fibrosis.Results In vehicle-treated foz/foz mice, hepatic expression of NLRP3, pro-IL-1β, active caspase-1 and IL-1β increased at 24weeks, in association with cholesterol crystal formation and NASH pathology; plasma IL-1β, IL-6, MCP-1, ALT/AST all increased. MCC950 treatment normalized hepatic caspase 1 and IL-1β expression, plasma IL-1β, MCP-1 and IL-6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as NASH pathology, and liver fibrosis. In vitro, cholesterol crystals activated Kupffer cells and macrophages to release IL-1β; MCC950 abolished this, and the associated neutrophil migration. MCD diet-fed mice developed fibrotic steatohepatitis; MCC950 suppressed the increase in hepatic caspase 1 and IL-1β, lowered numbers of macrophages and neutrophils in the liver, and improved liver fibrosis.Conclusion MCC950, an NLRP3 selective inhibitor, improved NAFLD pathology and fibrosis in obese diabetic mice. This is potentially attributable to the blockade of cholesterol crystal-mediated NLRP3 activation in myeloid cells. MCC950 reduced liver fibrosis in MCD-fed mice. Targeting NLRP3 is a logical direction in pharmacotherapy of NASH.Lay summary Fatty liver disease caused by being overweight with diabetes and a high risk of heart attack, termed non-alcoholic steatohepatitis (NASH), is the most common serious liver disease with no current treatment. There could be several causes of inflammation in NASH, but activation of a protein scaffold within cells termed the inflammasome (NLRP3) has been suggested to play a role. Here we show that cholesterol crystals could be one pathway to activate the inflammasome in NASH. We used a drug called MCC950, which has already been shown to block NLRP3 activation, in an attempt to reduce liver injury in NASH. This drug partly reversed liver inflammation, particularly in obese diabetic mice that most closely resembles the human context of NASH. In addition, such dampening of liver inflammation in NASH achieved with MCC950 partly reversed liver scarring, the process that links NASH to the development of cirrhosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2017.01.022

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Inflammasomes
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Self-citation
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Self-citation
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites†
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation
Rajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & Eklund, K. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011765 · Cited by 1,039
NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice
Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Hepatology · doi:10.1002/hep.26592 · Cited by 945
Self-citation
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
Cusi, K. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 940

Flagged first, then by citations

Show all 49 references

Sorted by citations

Items 201–300 of 999

Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Liver X Receptors Regulate Cholesterol Metabolism and Immunity in Hepatic Nonparenchymal Cells
Endo‐Umeda, K., & Makishima, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205045 · Cited by 68
Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-κB/NLRP3 signaling pathway
Deng, Y., Xu, Q., Chen, T., Ming, J., Wang, Y., Mao, L., Zhou, J., Sun, W., Zhou, Q. Y., Ren, H. G., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154241 · Cited by 71
The role of pyroptosis in inflammatory diseases
Chai, R., Li, Y., Shui, L., Ni, L., & Zhang, A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1173235 · Cited by 68
Dibutyl phthalate induces liver fibrosis via p38MAPK/NF-κB/NLRP3-mediated pyroptosis
Huo, S., Li, B., Du, J., Zhang, X., Zhang, J., Wang, Q., Song, M., & Li, Y. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.165500 · Cited by 67
Targeting cell death in NAFLD: mechanisms and targeted therapies
Xu, H., Wan, S., An, Y., Wu, Q., Xing, Y.-H., Deng, C.-H., Zhang, P., Long, Y., Xu, B.-T., & Jiang, Z. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02168-z · Cited by 72
Heme oxygenase-1 protects airway epithelium against apoptosis by targeting the proinflammatory NLRP3–RXR axis in asthma
Lv, J., Su, W., Yu, Q., Zhang, M., Di, C., Lin, X., Wu, M., & Xia, Z. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004950 · Cited by 67
The relevance of pyroptosis in the pathogenesis of liver diseases
Guo, H., Xie, M., Zhou, C., & Zheng, M. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.02.060 · Cited by 67
Mice Deficient in the IL-1β Activation Genes Prtn3, Elane, and Casp1 Are Protected Against the Development of Obesity-Induced NAFLD
Mirea, A.-M., Stienstra, R., Kanneganti, T., Tack, C. J., Chavakis, T., Toonen, E. J. M., & Joosten, L. A. B. (2020) · Inflammation · doi:10.1007/s10753-020-01190-4 · Cited by 67
Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome
Yang, G., Jang, J. H., Kim, S. W., Han, S., Ma, K., Jang, J.-K., Kang, H. C., Cho, Y., Lee, H. S., & Lee, J. Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082790 · Cited by 67
The Role of Melatonin on NLRP3 Inflammasome Activation in Diseases
Arioz, B. I., Tarakcioglu, E., Olcum, M., & Genç, Ş. (2021) · Antioxidants · doi:10.3390/antiox10071020 · Cited by 67
Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
Branković, M., Jovanović, I., Dukić, M., Radonjić, T., Oprić, S., Klašnja, S., & Zdravkovic, M. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095146 · Cited by 72
NLRP 3 inflammasome: A likely target for the treatment of allergic diseases
Xiao, Y., Xu, W., & Su, W. (2018) · Clinical & Experimental Allergy · doi:10.1111/cea.13190 · Cited by 66
Macrophages in metabolic associated fatty liver disease
Alharthi, J., Latchoumanin, O., George, J., & Eslam, M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i16.1861 · Cited by 65
Chemical hypoxia induces pro-inflammatory signals in fat-laden hepatocytes and contributes to cellular crosstalk with Kupffer cells through extracellular vesicles
Hernández, A., Geng, Y., Sepúlveda, R., Solı́s, N., Torres, J., Arab, J. P., Francisco Barrera, M., Cabrera, D., Moshage, H. J., & Arrese, M. A. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165753 · Cited by 64
Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF-κB/NLRP3 inflammasome circuit
Flores‐Costa, R., Duran‐Güell, M., Casulleras, M., López‐Vicario, C., Alcaraz‐Quiles, J., Díaz, A., Lozano, J. J., Titos, E., Hall, K., Sarno, R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000466117 · Cited by 64
NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice
Wang, X., Sun, K., Zhou, Y., Wang, H., Zhou, Y., Liu, S., Nie, Y., & Li, Y. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.11.009 · Cited by 64
An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: Insights into molecular mechanisms
Dinda, B., Dinda, M., Dinda, S., & De, U. C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115629 · Cited by 62
Regulation of Hepatic Stellate Cell Phenotypes in Metabolic Dysfunction–Associated Steatohepatitis
Kisseleva, T., Ganguly, S., Murad, R., Wang, A., & Brenner, D. A. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.010 · Cited by 75
Dexmedetomidine inhibits the NF-κB pathway and NLRP3 inflammasome to attenuate papain-induced osteoarthritis in rats
Cheng, F., Yan, F., Liu, Y.-P., Yan, C., Sun, K.-F., & He, X. (2019) · Pharmaceutical Biology · doi:10.1080/13880209.2019.1651874 · Cited by 64
Angiotensin (1–7) inhibits arecoline‐induced migration and collagen synthesis in human oral myofibroblasts via inhibiting NLRP3 inflammasome activation
You, Y., Huang, Y., Wang, D., Li, Y., Wang, G., Jin, S., Zhu, X., Wu, B., Du, X., & Li, X. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27267 · Cited by 63
NLRP3 inflammasome in hepatic diseases: A pharmacological target
Ramos‐Tovar, E., & Muriel, P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115861 · Cited by 66
NLRP3 Inflammasome and IL-33: Novel Players in Sterile Liver Inflammation
Neumann, K., Schiller, B., & Tiegs, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092732 · Cited by 64
Inflammatory Diseases and Vitamin E—What Do We Know and Where Do We Go?
Wallert, M., Börmel, L., & Lorkowski, S. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000097 · Cited by 68
Extracellular Vesicles as Inflammatory Drivers in NAFLD
Srinivas, A. N., Suresh, D., Santhekadur, P. K., Suvarna, D., & Kumar, D. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.627424 · Cited by 65
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH
Calcagno, D. M., Chu, A., Gaul, S., Taghdiri, N., Toomu, A., Leszczynska, A., Kaufmann, B. K., Papouchado, B. G., Wree, A., Geisler, L. J., et al. (2022) · Hepatology · doi:10.1002/hep.32320 · Cited by 62
Self-citation
The NLRP3 inflammasome in fibrosis and aging: The known unknowns
Liu, Y., Xu, X., Lei, W., Hou, Y., Zhang, Y., Tang, R., Yang, Z. P., Tian, Y., Zhu, Y., Wang, C., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101638 · Cited by 64
Breaking Boundaries: Chronic Diseases and the Frontiers of Immune Microenvironments
Li, G., Wan, Y., Jiao, A., Jiang, K., Cui, G., Tang, J., Yu, S., Hu, Z., Zhao, S., Yi, Z., et al. (2025) · Med Research · doi:10.1002/mdr2.70007 · Cited by 63
The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease
Engelmann, C., & Tacke, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020652 · Cited by 61
Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota
Han, R., Qiu, H., Zhong, J., Zheng, N., Li, B., Hong, Y., Ma, J., Wu, G., Chen, L., Sheng, L., et al. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153544 · Cited by 61
Novel Sesquiterpene Glycoside from Loquat Leaf Alleviates Type 2 Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease by Improving Insulin Resistance, Oxidative Stress, Inflammation, and Gut Microbiota Composition
Jian, C., Ding, X., Wu, R., Tong, B., Zhao, L., Lv, H., Meng, X., Liu, Y., Ren, B., Li, J., et al. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c05596 · Cited by 64
Interleukin-17 in Liver Disease Pathogenesis
Li, N., Yamamoto, G., Fuji, H., & Kisseleva, T. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730926 · Cited by 64
Bile Acids Activate NLRP3 Inflammasome, Promoting Murine Liver Inflammation or Fibrosis in a Cell Type-Specific Manner
Holtmann, T. M., Inzaugarat, M. E., Knorr, J., Geisler, L. J., Schulz, M., Bieghs, V., Frissen, M., Feldstein, A. E., Tacke, F., Trautwein, C., et al. (2021) · Cells · doi:10.3390/cells10102618 · Cited by 60
Self-citation
Cell Death in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Opportunities
García‐Pras, E., Fernández‐Iglesias, A., Gracia‐Sancho, J., & Pérez‐del‐Pulgar, S. (2021) · Cancers · doi:10.3390/cancers14010048 · Cited by 62
Vitamin D ameliorates high-fat-diet-induced hepatic injury via inhibiting pyroptosis and alters gut microbiota in rats
Zhang, X., Shang, X., Jin, S. K., Ma, Z., Wang, H., Ao, N., Yang, J., & Jian, D. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108894 · Cited by 60
Targeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches
Conte, E. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108031 · Cited by 61
The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease
Yang, Z., Danzeng, A., Liu, Q., Zeng, C., Xu, L., Mo, J., Ciren, P., Wang, X., Wang, C., Zhang, B., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87305 · Cited by 61
Taurine Alleviates Schistosoma-Induced Liver Injury by Inhibiting the TXNIP/NLRP3 Inflammasome Signal Pathway and Pyroptosis
Liu, X., Zhang, Y.-R., Cai, C., Ni, X.-Q., Zhu, Q., Ren, J.-L., Chen, Y., Zhang, L., Xue, C.-D., Zhao, J., et al. (2019) · Infection and Immunity · doi:10.1128/iai.00732-19 · Cited by 59
Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin
Yang, W., Liu, L., Wei, Y., Fang, C., Liu, S., Zhou, F., Li, Y., Zhao, G., Guo, Z., Luo, Y., et al. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-00508-y · Cited by 58
MCC950 as a promising candidate for blocking NLRP3 inflammasome activation: A review of preclinical research and future directions
Zheng, Y., Zhang, X., Wang, Z., Zhang, R., Wei, H., Xu, Y., Jiang, X., & Yang, L. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400459 · Cited by 61
NLRP3 inflammasome activates interleukin-23/interleukin-17 axis during ischaemia-reperfusion injury in cerebral ischaemia in mice
Wang, H., Zhong, D., Chen, H., Jin, J., Liu, Q., & Li, G. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.031 · Cited by 58
Metaflammation in glucolipid metabolic disorders: Pathogenesis and treatment
Xiong, P., Zhang, F., Liu, F., Zhao, J., Huang, X., Luo, D., & Guo, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114545 · Cited by 59
The Space of Disse: The Liver Hub in Health and Disease
Sanz-García, C., Fernández-Iglesias, A., Gracia-Sancho, J., Arráez-Aybar, L. A., Nevzorova, Y. A., & Cubero, F. J. (2021) · Livers · doi:10.3390/livers1010002 · Cited by 57
Automated computerized image analysis for the user-independent evaluation of disease severity in preclinical models of NAFLD/NASH
Rudder, M. D., Bouzin, C., Nachit, M., Louvegny, H., Velde, G. V., Julé, Y., & Leclercq, I. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0315-9 · Cited by 46
Role of Kupffer Cells in Driving Hepatic Inflammation and Fibrosis in HIV Infection
Zhang, L., & Bansal, M. B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01086 · Cited by 57
Epigenetic Regulation of Kupffer Cell Function in Health and Disease
Bennett, H., Troutman, T. D., Sakai, M., & Glass, C. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609618 · Cited by 66
NLRP3 Inflammasome Formation and Activation in Nonalcoholic Steatohepatitis: Therapeutic Target for Antimetabolic Syndrome Remedy FTZ
Chen, Y., He, X., Yuan, X., Hong, J., Bhat, O. M., Li, G., Li, P., & Guo, J. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2901871 · Cited by 56
Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models
Das, B., Sarkar, C., Rawat, V. S., Kalita, D., Deka, S., & Agnihotri, A. (2021) · Molecules · doi:10.3390/molecules26164996 · Cited by 60
Caffeine Inhibits NLRP3 Inflammasome Activation by Downregulating TLR4/MAPK/NF-κB Signaling Pathway in an Experimental NASH Model
Vargas-Pozada, E. E., Ramos‐Tovar, E., Rodríguez-Callejas, J. D., Cardoso-Lezama, I., Galindo‐Gómez, S., Talamás‐Lara, D., Vásquez-Garzón, V. R., Arellanes‐Robledo, J., Tsutsumi, V., Villa‐Treviño, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179954 · Cited by 56
Treating inflammation to combat non-alcoholic fatty liver disease
Wiering, L., & Tacke, F. (2022) · Journal of Endocrinology · doi:10.1530/joe-22-0194 · Cited by 59
Mechanisms of NLRP3 inflammasome-mediated hepatic stellate cell activation: Therapeutic potential for liver fibrosis
Charan, H. V., Dwivedi, D. K., Khan, S., & Jena, G. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.12.006 · Cited by 58
Microbial DNA enrichment promotes liver steatosis and fibrosis in the course of non‐alcoholic steatohepatitis
Luo, Z., Ji, Y., Zhang, D., Gao, H., Jin, Z., Yang, M., & Ying, W. (2022) · Acta Physiologica · doi:10.1111/apha.13827 · Cited by 55
S100A8-Mediated NLRP3 Inflammasome-Dependent Pyroptosis in Macrophages Facilitates Liver Fibrosis Progression
Liu, Y., Kong, X., You, Y., Xiang, L., Zhang, Y., Wu, R., Zhou, L., & Duan, L. (2022) · Cells · doi:10.3390/cells11223579 · Cited by 54
Neutrophil heterogeneity and plasticity: unveiling the multifaceted roles in health and disease
He, W., Yan, L., Hu, D., Hao, J., Liou, Y., & Luo, G. (2025) · MedComm · doi:10.1002/mco2.70063 · Cited by 60
Pattern Recognition Receptor-Mediated Chronic Inflammation in the Development and Progression of Obesity-Related Metabolic Diseases
Yu, L., Lǐ, Y., Du, C., Zhao, W., Zhang, H., Yang, Y., Sun, A., Song, X., & Feng, Z. (2019) · Mediators of Inflammation · doi:10.1155/2019/5271295 · Cited by 58
NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway
Dwivedi, D. K., & Jena, G. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01773-5 · Cited by 54
Effects of Lycium barbarum polysaccharides on immunological parameters, apoptosis, and growth performance of Nile tilapia (Oreochromis niloticus)
Zhang, X., Huang, K., Zhong, H., Ma, Y., Guo, Z., Tang, Z., Liang, J., Luo, Y., Su, Z., & Wang, L. (2019) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2019.12.068 · Cited by 54
Ginsenoside Rg1 ameliorates aging‑induced liver fibrosis by inhibiting the NOX4/NLRP3 inflammasome in SAMP8 mice
Li, Y., Zhang, D., Li, L., Han, Y., Dong, X., Liu, Y., Li, X., Li, W., & Li, W. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12441 · Cited by 53
Mitochondrial Targeting Therapeutics: Promising Role of Natural Products in Non-alcoholic Fatty Liver Disease
Xu, J., Shen, J., Yuan, R., Jia, B., Zhang, Y., Wang, S., Zhang, Y., Liu, M., & Wang, T. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.796207 · Cited by 53
Human-based systems: Mechanistic NASH modelling just around the corner?
Boeckmans, J., Natale, A., Buyl, K., Rogiers, V., Kock, J. D., Vanhaecke, T., & Rodrigues, R. M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.029 · Cited by 55
Effect of the Selective NLRP3 Inflammasome Inhibitor mcc950 on Transplantation Outcome in a Pig Liver Transplantation Model With Organs From Donors After Circulatory Death Preserved by Hypothermic Machine Perfusion
Yu, Y., Cheng, Y., Pan, Q., Zhang, Y., Jia, D., & Liu, Y. (2018) · Transplantation · doi:10.1097/tp.0000000000002461 · Cited by 53
Hepatic Regulator of G Protein Signaling 5 Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Transforming Growth Factor Beta–Activated Kinase 1–c‐Jun‐N‐Terminal Kinase/p38 Signaling
Wang, J., Ma, J., Nie, H.-Y., Zhang, X., Zhang, P., She, Z., Li, H., Ji, Y., & Cai, J. (2020) · Hepatology · doi:10.1002/hep.31242 · Cited by 53
Chlorogenic acid alleviated liver fibrosis in methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice and its mechanism
Miao, H., Ouyang, H., Guo, Q., Wei, M., Lü, B., Kai, G., & Ji, L. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109020 · Cited by 52
Macrophages as key regulators of liver health and disease
Papachristoforou, E., & Ramachandran, P. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.006 · Cited by 56
NLRP3 Inflammasome in Acute and Chronic Liver Diseases
Sayaf, K., Battistella, S., & Russo, F. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084537 · Cited by 55
Activated TNF-α/RIPK3 signaling is involved in prolonged high fat diet-stimulated hepatic inflammation and lipid accumulation: inhibition by dietary fisetin intervention
Xu, M., Ge, C., Qin, Y., Gu, T.-T., Lv, J., Wang, S., Ma, Y., Lou, D., Li, Q., Hu, L., et al. (2019) · Food & Function · doi:10.1039/c8fo01615a · Cited by 50
MicroRNA-29a Disrupts DNMT3b to Ameliorate Diet-Induced Non-Alcoholic Steatohepatitis in Mice
Yang, Y., Kuo, H., Wang, F., & Huang, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061499 · Cited by 51
Efficacy and Mechanism of Polymerized Anthocyanin from Grape-Skin Extract on High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease
Fan, M., Choi, Y., Tang, Y., Bae, S. M., Yang, H. P., & Kim, E. (2019) · Nutrients · doi:10.3390/nu11112586 · Cited by 53
MCC950, a NLRP3 inhibitor, ameliorates lipopolysaccharide-induced lung inflammation in mice
Wang, L., Wu, L., Zhang, S.-J., & Li, Y. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115954 · Cited by 51
NLRP3 inflammasome priming and activation in cholestatic liver injury via the sphingosine 1-phosphate/S1P receptor 2/Gα(12/13)/MAPK signaling pathway
Hou, L., Zhang, Z., Yang, L., Chang, N., Zhao, X., Zhou, X., Yang, L., & Li, L. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02032-4 · Cited by 51
Attenuating Effects of Dieckol on High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Decreasing the NLRP3 Inflammasome and Pyroptosis
Oh, S., Son, M., Byun, K.-A., Jang, J. T., Choi, C. H., Son, K. H., & Byun, K. (2021) · Marine Drugs · doi:10.3390/md19060318 · Cited by 52
Cell-specific Deletion of NLRP3 Inflammasome Identifies Myeloid Cells as Key Drivers of Liver Inflammation and Fibrosis in Murine Steatohepatitis
Kaufmann, B., Kui, L., Reca, A., Leszczynska, A., Kim, A. D., Booshehri, L. M., Wree, A., Friess, H., Hartmann, D., Broderick, L., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.06.007 · Cited by 51
Self-citation
Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
Li, C., Yang, J., Wang, Y., Qi, Y., Yang, W., & Li, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01247 · Cited by 51
Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis
Torres, S., Segalés, P., García‐Ruiz, C., & Fernández-Checa, J. C. (2022) · Cells · doi:10.3390/cells11091475 · Cited by 51
Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease
Pan, J., Zhou, W., Xu, R., Xing, L., Ji, G., & Dang, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113127 · Cited by 50
Innate Immunity and MASLD
Meyer, M., Schwärzler, J., Jukic, A., & Tilg, H. (2024) · Biomolecules · doi:10.3390/biom14040476 · Cited by 50
The role of IFN in the development of NAFLD and NASH
Møhlenberg, M., Terczyńska‐Dyla, E., Thomsen, K. L., George, J., Eslam, M., Grønbæk, H., & Hartmann, R. (2018) · Cytokine · doi:10.1016/j.cyto.2018.08.013 · Cited by 50
Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis
Baeza-Raja, B., Goodyear, A., Liu, X., Lam, K., Yamamoto, L., Li, Y., Dodson, G. S., Takeuchi, T., Kisseleva, T., Brenner, D. A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234038 · Cited by 53
The complex interplay between endoplasmic reticulum stress and the NLRP3 inflammasome: a potential therapeutic target for inflammatory disorders
Chong, W. C., Shastri, M. D., Peterson, G. M., Patel, R. P., Pathinayake, P. S., Dua, K., Hansbro, N. G., Hsu, A., Wark, P. A. B., Shukla, S. D., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1247 · Cited by 54
Self-citation
CD5L is a pleiotropic player in liver fibrosis controlling damage, fibrosis and immune cell content
Bárcena, C., Aran, G., Perea, L., Sanjurjo, L., Téllez, É., Oncins, A., Masnou, H., Serra, I., Garcı́a-Gallo, M., Kremer, L., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.052 · Cited by 49
Revealing the role of peroxisome proliferator-activated receptor β/δ in nonalcoholic fatty liver disease
Zarei, M., Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154342 · Cited by 49
Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease
He, L., Yao, D.-H., Wang, L., Zhang, L., & Bai, X. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.761836 · Cited by 49
Neutrophil extracellular traps enriched with IL-1β and IL-17A participate in the hepatic inflammatory process of patients with non-alcoholic steatohepatitis
Arelaki, S., Κoletsa, T., Sinakos, E., Papadopoulos, V. P., Arvanitakis, K., Skendros, P., Akriviadis, E. A., Ritis, K., Germanidis, G. S., & Hytiroglou, P. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03330-7 · Cited by 50
Melatonin Suppresses NLRP3 Inflammasome Activation via TLR4/NF-κB and P2X7R Signaling in High-Fat Diet-Induced Murine NASH Model
Saha, M., Manna, K., & Saha, K. D. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s343236 · Cited by 48
Gynostemma pentaphyllum polysaccharides ameliorate non-alcoholic steatohepatitis in mice associated with gut microbiota and the TLR2/NLRP3 pathway
Yue, S., Tan, Y.-Y., Zhang, L., Zhang, B., Jiang, F.-Y., Ji, G., Liu, B., & Wang, R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.885039 · Cited by 48
Fungal infections and the fungal microbiome in hepatobiliary disorders
Hartmann, P., & Schnabl, B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.12.006 · Cited by 50
The gut microbiota-bile acid axis in cholestatic liver disease
Sun, D., Xie, C., Zhao, Y. M., Liao, J., Li, S., Zhang, Y., Wang, D., Hua, K., Gu, Y., Du, J., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00830-x · Cited by 56
Tim-4 Inhibits NLRP3 Inflammasome via the LKB1/AMPKα Pathway in Macrophages
Liu, W., Bai, F., Wang, H., Liang, Y., Du, X., Liu, C., Cai, D., Peng, J., Zhong, G., Liang, X., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900117 · Cited by 49
MRG15 aggravates non-alcoholic steatohepatitis progression by regulating the mitochondrial proteolytic degradation of TUFM
Tian, C., Min, X., Zhao, Y., Wang, Y., Wu, X., Liu, S., Dou, W., Zhou, T., Liu, Y., Luo, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.017 · Cited by 49
Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor
Shen, D.-M., Byth, K. F., Bertheloot, D., Braams, S., Bradley, S., Dean, D. C., Dekker, C., El‐Kattan, A. F., Franchi, L., Glick, G. D., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02759 · Cited by 50
Non-parenchymal hepatic cell lipotoxicity and the coordinated progression of non-alcoholic fatty liver disease and atherosclerosis
Peters, K. M., Wilson, R. B., & Borradaile, N. M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000535 · Cited by 47
Androgen aggravates liver fibrosis by activation of NLRP3 inflammasome in CCl 4 -induced liver injury mouse model
Ma, X., Zhou, Y., Qiao, B., Jiang, S., Shen, Q., Han, Y., Liu, A., Chen, X., Wei, L., Zhou, L., et al. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00427.2019 · Cited by 47
Pyroptosis in Steatohepatitis and Liver Diseases
Knorr, J., Wree, A., & Feldstein, A. E. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167271 · Cited by 48
Self-citation
L-plastin enhances NLRP3 inflammasome assembly and bleomycin-induced lung fibrosis
Joshi, H. P., Almgren‐Bell, A., Anaya, E. P., Todd, E. M., Dyken, S. J. V., Seth, A., McIntire, K. M., Singamaneni, S., Sutterwala, F. S., & Morley, S. C. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110507 · Cited by 49
From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
Samy, A. M., Kandeil, M. A., Sabry, D., Abdel-Ghany, A. A., & Mahmoud, M. O. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30387 · Cited by 55
Central blockade of NLRP3 reduces blood pressure via regulating inflammation microenvironment and neurohormonal excitation in salt-induced prehypertensive rats
Wang, M.-L., Kang, Y., Li, X., Su, Q., Li, H., Liu, K., Fu, L., Saahene, R. O., Li, Y., Tan, H., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1131-7 · Cited by 46
Autophagic-CTSB-inflammasome axis modulates hepatic stellate cells activation in arsenic-induced liver fibrosis
Tao, Y., Qiu, T., Yao, X., Jiang, L., Wang, N., Jia, X., Wei, S., Wang, Z., Pei, P., Zhang, J., et al. (2019) · Chemosphere · doi:10.1016/j.chemosphere.2019.124959 · Cited by 46
Calcipotriol Inhibits NLRP3 Signal Through YAP1 Activation to Alleviate Cholestatic Liver Injury and Fibrosis
Wang, X., Wang, G., Qu, J., Yuan, Z., Pan, R., & Li, K. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00200 · Cited by 46
Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting
Singanayagam, A., & Triantafyllou, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661182 · Cited by 47
Upregulated NLRP3 inflammasome activation is attenuated by anthocyanins in patients with nonalcoholic fatty liver disease: A case-control and an intervention study
Zhu, X., Lin, X., Zhang, P., Liu, Y., Ling, W., & Guo, H. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101843 · Cited by 46

Authors: Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., Masters, S. L., Schroder, K., Cooper, M. A., Feldstein, A. E., & Farrell, G. C.
Affiliations: Australian National University (AU)
University of California San Diego (US)
The University of Queensland (AU)
University of Washington (US)
Walter and Eliza Hall Institute of Medical Research (AU)
Corresponding author: Farrell, Geoffrey C.
ORCID: Mridha, Auvro R.
Wree, Alexander
Robertson, Avril A.B.
Yeh, Matthew M.
Johnson, Casey D.
Haczeyni, Fahrettin
Savard, Christopher
Ioannou, George N.
Masters, Seth L.
Schroder, Kate
Cooper, Matthew A.
Feldstein, Ariel E.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2017-05
Volume: 66
Issue: 5
Pages: 1037-1046
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2017.01.022
PMC: PMC6536116
OpenAlex: W2585046292
Cited by: 1,110
References: 49
Citations by year: 2026: 117 · 2025: 147 · 2024: 126 · 2023: 150 · 2022: 160 · 2021: 143 · 2020: 121 · 2019: 61 · 2018: 70 · 2017: 14
FWCI: 57.20
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
ANU Open Research (Australian National University) (submittedVersion, cc-by-nc-nd)
RWTH Publications (RWTH Aachen) (submittedVersion)
Funders: National Institute on Alcohol Abuse and Alcoholism (U01AA022489, R21AA023574)
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK113592)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: NLRP3 inflammasome, MCC950, nonalcoholic steatohepatitis, liver fibrosis, liver inflammation, IL-1β, caspase-1, cholesterol crystals, Kupffer cells, macrophages, neutrophil migration, methionine-choline-deficient diet, atherogenic diet, myeloid cells
MeSH terms: NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Disease Models, Animal, Female, Furans, Hepatitis, Heterocyclic Compounds, 4 or More Rings, Indenes, Liver Cirrhosis, Experimental, Sulfonamides, Sulfones, NF-kappa B, Reactive Oxygen Species, Mice, Interleukin-1beta, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks